Explore more press releases
Topics
Period
recent search
Showing: 1 – 05 of 229 Press Releases
22 December 2025
22 December 2025
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed…
19 December 2025
19 December 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva…
15 December 2025
15 December 2025
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.
01 December 2025
01 December 2025
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
PARIS, FRANCE, 1 DECEMBER 2025 – It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025.
07 November 2025
07 November 2025
Your dedicated contacts
-
Media Relations
-
